ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2137

Linear Extrapolation of Missing Radiographic Progression Scores Does Not Spuriously overestimate overall Radiographic Progression in Rheumatoid Arthritis

Iris Markusse1, Robert Landewé2,3, Meilien Ho4, Martin Jenkins4 and Desiree van der Heijde5, 1Leiden University Medical Center, Leiden, Netherlands, 2Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 3Atrium Medical Center, Heerlen, Netherlands, 4AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Missing data, multiple imputation, radiography and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Various Imaging Techniques

Session Type: Abstract Submissions (ACR)

Background/Purpose : Linear Extrapolation (LE) is a frequently applied method to impute missing radiographic data in trials. However, there is frequent critique that LE overestimates overall progression. Therefore, ‘Last Observation Carried Forward’ (LOCF) has been suggested by regulatory bodies as a more conservative method. In the OSKIRA-1 trial (NCT01197521), radiographs were taken at the 12 week (wk) time point, where early escape was possible, in all patients thus providing an excellent opportunity to compare extrapolations based upon LOCF and LE to the truly observed radiographic progression.

Methods : The phase 3 OSKIRA-1 trial enrolled rheumatoid arthritis patients (pts) with an inadequate response to methotrexate. Films of hands and feet were obtained at baseline, wk 12 and 24 in those pts still on study, and were assessed by two readers in random time order using the van der Heijde modified total Sharp score (mTSS). Ten datasets with an artificially, randomly selected sample of 20% missing wk 24 data were created, based upon pts with complete sets of films. First, these missing data were imputed using LE as (mTSS at wk 12 + progression wk 0 – 12, corrected for the actual days between films). Second, the missing data were imputed using LOCF. This approach was iterated for 10 random samples with 50% missing data and 10 random samples with 80% missing data. The datasets obtained with LE and LOCF were compared to the dataset with truly observed data at week 24.

Results : Complete sets of films were available for 579 pts. All our analyses were essentially similar in the 3 treatment arms, so here we present the analysis on pooled data. Mean (SD) observed progression from baseline to wk 24 was 0.33 (2.42). Table 1 shows the average (SD) and range of the mean radiographic progression in the 10 random samples. Using LE, the mean progression estimates were close to the observed data, and not affected by the proportion of missing data. The SD however increased by increasing proportions of missing data. Using LOCF, the mean progression estimates were consistently lower than the observed progression. LOCF increasingly underestimated observed progression by increasing proportions of missing data. As expected, the SD of the LOCF estimates remained stable by increasing proportions of missing data.  

Conclusion : In contrast to LOCF, linear extrapolation gives a more accurate impression of true mean radiographic progression at a group level and is less influenced by the proportion of missing data. Since LE inflates the standard deviation of progression scores, the statistical power to detect a significant difference between active treatment and placebo may decrease by increasing proportions of missingness. LE does therefore not overestimate mean treatment effects and is a more robust method than LOCF in this respect.

Table 1: Change in the van der Heijde modified total Sharp score (mTSS) from baseline to week 24.

 

Observed change in mTSS in patients completing 24 weeks, mean (SD): 0.33 (2.42)

Method

Mean of the mean*

Mean of the SD*

Minimum mean*

Maximum mean*

Minimum SD*

Maximum SD*

20% missing data

LOCF

0.29

2.43

0.28

0.32

2.38

2.48

LE

0.32

3.02

0.27

0.39

2.60

4.44

50% missing data

LOCF

0.25

2.41

0.21

0.29

2.32

2.49

LE

0.34

3.83

0.22

0.42

2.73

4.61

80% missing data

LOCF

0.19

2.41

0.18

0.21

2.37

2.44

LE

0.30

4.19

0.21

0.36

3.05

4.74

*of 10 random samples

LE, linear extrapolation; LOCF, last observation carried forward; mTSS, van der Heijde modified total Sharp score; SD, standard deviation.


Disclosure:

I. Markusse,
None;

R. Landewé,

Rheumatology Consulting BV,

9;

M. Ho,

AstraZeneca,

3,

AstraZeneca,

1;

M. Jenkins,

AstraZeneca,

3,

AstraZeneca,

1;

D. van der Heijde,

AstraZeneca,

9,

Imaging Rheumatology BV,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/linear-extrapolation-of-missing-radiographic-progression-scores-does-not-spuriously-overestimate-overall-radiographic-progression-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology